Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines

Denis S. Fedorinov; Vladimir K. Lyadov; Dmitriy A. Sychev

doi:10.1515/dmpt-2021-0162

Article

Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines

Denis S. Fedorinov , Vladimir K. Lyadov and Dmitriy A. Sychev

Published/Copyright: November 30, 2021

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 37 Issue 3

Abstract

This review aimed to summarize the pharmacogenetic studies of the most commonly used drugs in the chemotherapy of gastrointestinal (GI) tumors: oxaliplatin, irinotecan, and fluoropyrimidines. So far, it has not been possible to develop an effective genotype-based approach for oxaliplatin. More and more evidence is emerging in favor of the fact that the choice of a dose of fluorouracil based on pharmacogenetic testing according to DPYD*2A, can be not only effective but also cost-effective. Additional, well-planned trials of the UGT1A1 genotype-based approach to irinotecan therapy are predicted to reduce adverse drug events in people with the UGT1A1*28/*28 genotypes and improve treatment efficacy in the rest of the patients, which might be cost-effective.

Keywords: dihydropyrimidine dehydrogenase (DPYD); excision repair and cross-complementation (ERCC); fluoropyrimidines; GSTM1; GSTT1; irinotecan; oxaliplatin; UGT1A1

Corresponding author: Denis S. Fedorinov, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare, 2/1 Barrikadnaya Str., Moscow, 125993, Russian Federation; and City Clinical Cancer Hospital, № 1.17/1 Baumanskaya Str., Moscow, 105005, Russian Federation, E-mail: deni_fe@mail.ru

Funding source: Russian Research Foundation

Award Identifier / Grant number: 20-75-10158

Research funding: This study was supported by the Russian Research Foundation (Grant No. 20-75-10158) ‘Body composition based pharmacokinetic and pharmacogenetic approach to the chemotherapy of gastrointestinal tumors’.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: Authors state no conflict of interest.
Informed consent: Not applicable.
Ethical approval: Not applicable.

References

1. Cancer stat facts [Online]. Available from: https://seer.cancer.gov/statfacts.Search in Google Scholar

2. Onakpoya, IJ, Heneghan, CJ, Aronson, JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol 2016;46:477–89. https://doi.org/10.3109/10408444.2016.1149452.Search in Google Scholar

3. Meulendijks, D, Henricks, LM, Sonke, GS, Deenen, MJ, Froehlich, TK, Amstutz, U, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639–50. https://doi.org/10.1016/s1470-2045(15)00286-7.Search in Google Scholar

4. Shahnam, A, Ridha, Z, Wiese, MD, Kichenadasse, G, Sorich, MJ. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics 2016;17:1725–32. https://doi.org/10.2217/pgs-2016-0102.Search in Google Scholar

5. Dias, MM, Pignon, J-P, Karapetis, CS, Boige, V, Glimelius, B, Kweekel, DM, et al.. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J 2014;14:424–31. https://doi.org/10.1038/tpj.2014.16.Search in Google Scholar

6. Graham, MA, Lockwood, GF, Greenslade, D, Brienza, S, Bayssas, M, Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res Off J Am Assoc Cancer Res 2000;6:1205–18.Search in Google Scholar

7. Hoeijmakers, JH. Nucleotide excision repair. II: from yeast to mammals. Trends Genet 1993;9:211–7. https://doi.org/10.1016/0168-9525(93)90121-w.Search in Google Scholar

8. Abad, A, Martínez-Balibrea, E, Viéitez, JM, Alonso-Orduña, V, García Alfonso, P, Manzano, JL, et al.. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol 2018;29:439–44. https://doi.org/10.1093/annonc/mdx737.Search in Google Scholar PubMed

9. Catenacci, DVT, Chase, L, Lomnicki, S, Karrison, T, de Wilton Marsh, R, Rampurwala, MM, et al.. Evaluation of the association of perioperative UGT1A1 genotype-dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial. JAMA Netw Open 2020;3:e1921290. https://doi.org/10.1001/jamanetworkopen.2019.21290.Search in Google Scholar PubMed

10. McWilliams, RR, Foster, NR, Mahoney, MR, Smyrk, TC, Murray, JA, Ames, MM, et al.. North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 2017;123:3494–501. https://doi.org/10.1002/cncr.30766.Search in Google Scholar PubMed PubMed Central

11. Maekawa, K, Harakawa, N, Yoshimura, T, Kim, S-R, Fujimura, Y, Aohara, F, et al.. CYP3A4 * 16 and CYP3A4 * 18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 2010;38:2100–4. https://doi.org/10.1124/dmd.110.034140.Search in Google Scholar PubMed

12. Hahn, RZ, Antunes, MV, Verza, SG, Perassolo, MS, Suyenaga, ES, Schwartsmann, G, et al.. Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. Curr Med Chem 2019;26:2085–107. https://doi.org/10.2174/0929867325666180622141101.Search in Google Scholar PubMed

13. Lévesque, E, Bélanger, A-S, Harvey, M, Couture, F, Jonker, D, Innocenti, F, et al.. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. J Pharmacol Exp Therapeut 2013;345:95–101.10.1124/jpet.112.202242Search in Google Scholar PubMed PubMed Central

14. O’Dwyer, PJ, Catalano, RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24:4534–8.10.1200/JCO.2006.07.3031Search in Google Scholar PubMed

15. Toffoli, G, Cecchin, E, Corona, G, Russo, A, Buonadonna, A, D’Andrea, M, et al.. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061–8. https://doi.org/10.1200/jco.2005.05.5400.Search in Google Scholar PubMed

16. Páez, D, Tobeña, M, Fernández-Plana, J, Sebio, A, Virgili, AC, Cirera, L, et al.. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer 2019;120:190–5.10.1038/s41416-018-0348-7Search in Google Scholar PubMed PubMed Central

17. Toffoli, G, Cecchin, E, Gasparini, G, D’Andrea, M, Azzarello, G, Basso, U, et al.. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866–71. https://doi.org/10.1200/jco.2009.23.6125.Search in Google Scholar

18. Kroetz, DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:4225–7. https://doi.org/10.1200/jco.2006.07.2355.Search in Google Scholar PubMed

19. de Man, FM, Goey, AKL, van Schaik, RHN, Mathijssen, RHJ, Bins, S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018;57:1229–54. https://doi.org/10.1007/s40262-018-0644-7.Search in Google Scholar PubMed PubMed Central

20. Hoff, PM, Ansari, R, Batist, G, Cox, J, Kocha, W, Kuperminc, M, et al.. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92. https://doi.org/10.1200/jco.2001.19.8.2282.Search in Google Scholar PubMed

21. van Kuilenburg, ABP, Meinsma, R, Zonnenberg, BA, Zoetekouw, L, Baas, F, Matsuda, K, et al.. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res Off J Am Assoc Cancer Res 2003;9:4363–7.Search in Google Scholar

22. Van Kuilenburg, AB, van Lenthe, H, Blom, MJ, Mul, EP, Van Gennip, AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999;79:620–6. https://doi.org/10.1038/sj.bjc.6690097.Search in Google Scholar PubMed PubMed Central

23. Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, et al.. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 2011;89:662–73. https://doi.org/10.1038/clpt.2011.34.Search in Google Scholar PubMed

24. `van Kuilenburg, ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939–50. https://doi.org/10.1016/j.ejca.2003.12.004.Search in Google Scholar PubMed

25. Deenen, MJ, Meulendijks, D, Cats, A, Sechterberger, MK, Severens, JL, Boot, H, et al.. Upfront genotyping of DPYD * 2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016;34:227–34. https://doi.org/10.1200/jco.2015.63.1325.Search in Google Scholar

26. Henricks, LM, van Merendonk, LN, Meulendijks, D, Deenen, MJ, Beijnen, JH, de Boer, A, et al.. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: a matched pair analysis: matched pair analysis of DPYD *2A carriers. Int J Cancer 2019;144:2347–54. https://doi.org/10.1002/ijc.32022.Search in Google Scholar PubMed

27. Kawakami, K, Salonga, D, Park, JM, Danenberg, KD, Uetake, H, Brabender, J, et al.. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res Off J Am Assoc Cancer Res 2001;7:4096–101.Search in Google Scholar

28. Soo, RA, Syn, N, Lee, S-C, Wang, L, Lim, X-Y, Loh, M, et al.. Pharmacogenetics-guided phase I study of capecitabine on an intermittent schedule in patients with advanced or metastatic solid tumours. Sci Rep 2016;6:27826. https://doi.org/10.1038/srep27826.Search in Google Scholar PubMed PubMed Central

Received: 2021-04-25

Accepted: 2021-09-13

Published Online: 2021-11-30

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2021-0162

Keywords for this article

dihydropyrimidine dehydrogenase (DPYD); excision repair and cross-complementation (ERCC); fluoropyrimidines; GSTM1; GSTT1; irinotecan; oxaliplatin; UGT1A1